J Bone Miner Metab:老年人低血清维生素D水平与其髋部骨折的风险增加有关

2022-07-22 sunshine MedSci原创

维生素D缺乏是世界各国老年人中最常见的问题之一。重要的是,维生素D在钙的平衡以及随后的骨代谢中具有关键作用。

维生素D缺乏是世界各国老年人中最常见的问题之一。重要的是,维生素D在钙的平衡以及随后的骨代谢中具有关键作用。尽管之前的一些荟萃分析研究显示,低血清25(OH)维生素D水平会增加髋部总骨折的风险,但另一项荟萃分析研究显示,在任何给药剂量下,老年人补充维生素D对髋部骨折都没有预防作用。鉴于这些研究结果的不一致,需要新的研究来综合现有研究进行系统的分析。近日,发表于J Bone Miner Metab的一项系统回顾和荟萃分析旨在探索老年人血清维生素D水平和髋部骨折之间的关系。

研究人员利用PubMed、Web of Science和Scopus来确定概述血清25OHD与老年患者髋部骨折发生之间关系的研究。该分析使用随机效应模型计算髋部骨折的几率(OR)。

结果,这项研究共纳入了28项研究,包括61744名老年人和9767例(15.81%)髋部骨折。分析结果显示,在老年人维生素D最低与最高组别中,髋部骨折的集合OR为1.80(95% CI 1.56-2.07,P≤0.001),改良OR等于1.40(95% CI 1.20-1.63 P≤0.001)。亚组分析显示,髋部骨折的OR在病例对照研究中为2.16(1.49-3.11,P≤0.001);在队列研究中为1.52(1.29-1.79,P=0.001);在病例-队列研究中为1.41(1.18-1.70,P≤0.001)。

综上所述,该研究结果表明,老年人的低血清维生素D水平与髋部骨折的风险增加有关。因此,支持鼓励在年龄增长期间以适当的间隔监测血清25(OH)D水平,以减少老年人髋部骨折的风险。

原始出处:

Shahrzad Habibi Ghahfarrokhi, et al., Relationship between serum vitamin D and hip fracture in the elderly: a systematic review and meta-analysis. J Bone Miner Metab. 2022 Jul;40(4):541-553. doi: 10.1007/s00774-022-01333-7.  

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1888451, encodeId=418418884511e, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Nov 27 18:34:55 CST 2022, time=2022-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915234, encodeId=6b481915234b8, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Tue Nov 29 10:34:55 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897039, encodeId=62bc189e039bb, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Oct 27 03:34:55 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234646, encodeId=8a2d12346467f, content=插眼, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0a75723422, createdName=ms6000000804939172, createdTime=Mon Jul 25 17:33:06 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234096, encodeId=83201234096b6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Fri Jul 22 23:30:33 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408522, encodeId=535e14085229c, content=<a href='/topic/show?id=92021020e814' target=_blank style='color:#2F92EE;'>#髋部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102078, encryptionId=92021020e814, topicName=髋部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=293f2750231, createdName=liuquan, createdTime=Fri Jul 22 14:34:55 CST 2022, time=2022-07-22, status=1, ipAttribution=)]
    2022-11-27 医者仁心
  2. [GetPortalCommentsPageByObjectIdResponse(id=1888451, encodeId=418418884511e, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Nov 27 18:34:55 CST 2022, time=2022-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915234, encodeId=6b481915234b8, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Tue Nov 29 10:34:55 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897039, encodeId=62bc189e039bb, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Oct 27 03:34:55 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234646, encodeId=8a2d12346467f, content=插眼, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0a75723422, createdName=ms6000000804939172, createdTime=Mon Jul 25 17:33:06 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234096, encodeId=83201234096b6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Fri Jul 22 23:30:33 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408522, encodeId=535e14085229c, content=<a href='/topic/show?id=92021020e814' target=_blank style='color:#2F92EE;'>#髋部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102078, encryptionId=92021020e814, topicName=髋部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=293f2750231, createdName=liuquan, createdTime=Fri Jul 22 14:34:55 CST 2022, time=2022-07-22, status=1, ipAttribution=)]
    2022-11-29 apoenzyme
  3. [GetPortalCommentsPageByObjectIdResponse(id=1888451, encodeId=418418884511e, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Nov 27 18:34:55 CST 2022, time=2022-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915234, encodeId=6b481915234b8, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Tue Nov 29 10:34:55 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897039, encodeId=62bc189e039bb, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Oct 27 03:34:55 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234646, encodeId=8a2d12346467f, content=插眼, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0a75723422, createdName=ms6000000804939172, createdTime=Mon Jul 25 17:33:06 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234096, encodeId=83201234096b6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Fri Jul 22 23:30:33 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408522, encodeId=535e14085229c, content=<a href='/topic/show?id=92021020e814' target=_blank style='color:#2F92EE;'>#髋部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102078, encryptionId=92021020e814, topicName=髋部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=293f2750231, createdName=liuquan, createdTime=Fri Jul 22 14:34:55 CST 2022, time=2022-07-22, status=1, ipAttribution=)]
    2022-10-27 一闲
  4. [GetPortalCommentsPageByObjectIdResponse(id=1888451, encodeId=418418884511e, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Nov 27 18:34:55 CST 2022, time=2022-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915234, encodeId=6b481915234b8, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Tue Nov 29 10:34:55 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897039, encodeId=62bc189e039bb, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Oct 27 03:34:55 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234646, encodeId=8a2d12346467f, content=插眼, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0a75723422, createdName=ms6000000804939172, createdTime=Mon Jul 25 17:33:06 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234096, encodeId=83201234096b6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Fri Jul 22 23:30:33 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408522, encodeId=535e14085229c, content=<a href='/topic/show?id=92021020e814' target=_blank style='color:#2F92EE;'>#髋部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102078, encryptionId=92021020e814, topicName=髋部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=293f2750231, createdName=liuquan, createdTime=Fri Jul 22 14:34:55 CST 2022, time=2022-07-22, status=1, ipAttribution=)]
    2022-07-25 ms6000000804939172

    插眼

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1888451, encodeId=418418884511e, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Nov 27 18:34:55 CST 2022, time=2022-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915234, encodeId=6b481915234b8, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Tue Nov 29 10:34:55 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897039, encodeId=62bc189e039bb, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Oct 27 03:34:55 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234646, encodeId=8a2d12346467f, content=插眼, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0a75723422, createdName=ms6000000804939172, createdTime=Mon Jul 25 17:33:06 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234096, encodeId=83201234096b6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Fri Jul 22 23:30:33 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408522, encodeId=535e14085229c, content=<a href='/topic/show?id=92021020e814' target=_blank style='color:#2F92EE;'>#髋部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102078, encryptionId=92021020e814, topicName=髋部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=293f2750231, createdName=liuquan, createdTime=Fri Jul 22 14:34:55 CST 2022, time=2022-07-22, status=1, ipAttribution=)]
    2022-07-22 12192b1am98暂无昵称

    学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1888451, encodeId=418418884511e, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Nov 27 18:34:55 CST 2022, time=2022-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915234, encodeId=6b481915234b8, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Tue Nov 29 10:34:55 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897039, encodeId=62bc189e039bb, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Oct 27 03:34:55 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234646, encodeId=8a2d12346467f, content=插眼, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0a75723422, createdName=ms6000000804939172, createdTime=Mon Jul 25 17:33:06 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234096, encodeId=83201234096b6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Fri Jul 22 23:30:33 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408522, encodeId=535e14085229c, content=<a href='/topic/show?id=92021020e814' target=_blank style='color:#2F92EE;'>#髋部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102078, encryptionId=92021020e814, topicName=髋部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=293f2750231, createdName=liuquan, createdTime=Fri Jul 22 14:34:55 CST 2022, time=2022-07-22, status=1, ipAttribution=)]
    2022-07-22 liuquan

相关资讯

Bone Joint J:肩胛骨未愈合处理,血管化植骨的效果并不优于非血管化植骨

近日,发表于Bone Joint J的一项系统综述旨在确定在肩胛骨未愈合的手术治疗中,血管化与非血管化移植技术的愈合率。次要目的是确定所使用的固定技术、植骨来源的影响。

Biomed Res Int:不同内固定结合不同植骨术治疗老年人不稳定胸腰椎骨折的生物力学分析

作为老年患者常见的脊柱疾病,脊柱骨折常与骨质疏松症有关。然而,老年患者的骨密度低,身体素质差,常伴有其他系统性疾病。因此,选择合适的内固定系统和有效的手术方法对解决老年患者的内固定失败起着决定性作用。

非典型股骨骨折(Atypical Femur Fractures)的诊断标准与影像表现

非典型股骨骨折(Atypical Femur Fractures)的诊断标准与影像表现。

骨折病人并发症及石膏固定的护理措施

骨折病人并发症及石膏固定的护理措施

Front Endocrinol (Lausanne):使用艾地卡醇可以改善不同部位的骨密度和骨折

用ED-71可以改善不同部位的BMD和骨折,尤其是与阿法骨化醇或与双膦酸盐联合使用的骨质疏松症患者相比。